Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 21, 2026, 5:52 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 1,396 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Genentech, Inc. Clear all
Completed Phase 3 Interventional Results available

Rituximab in Rheumatoid Arthritis Lung Disease

NCT00578565
View directory record Official record
Conditions
Rheumatoid Arthritis, Interstitial Pneumonia
Interventions
Rituximab
Drug
Lead sponsor
Eric Matteson
Other
Eligibility
18 Years to 80 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2011
U.S. locations
2
States / cities
Boston, Massachusetts • Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 1, 2012 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 2 Interventional

A Study Evaluating the Efficacy and Safety of MEGF0444A Dosed to Progression in Combination With Bevacizumab and mFOLFOX-6 in Participants With Previously Untreated Metastatic Colorectal Cancer

NCT01399684
View directory record Official record
Conditions
Metastatic Colorectal Cancer
Interventions
5-Fluorouracil, Bevacizumab, Folinic acid, MEGF0444A, Oxaliplatin, Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
127 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
23
States / cities
Birmingham, Alabama • Scottsdale, Arizona • Bakersfield, California + 18 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2016 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Results available

TARCEVA (Erlotinib) in Combination With Chemoradiation in Patients With Stage IIIA/B Non-Small Cell Lung Cancer (NSCLC)

NCT00563784
View directory record Official record
Conditions
Non-Small Cell Lung Cancer, Lung Cancer
Interventions
Erlotinib, Carboplatin, Paclitaxel, Radiation Therapy
Drug · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
68 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2018
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Nov 20, 2019 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine and Erlotinib in Treating Patients With Metastatic or Recurrent Pancreatic Cancer

NCT00810719
View directory record Official record
Conditions
Pancreatic Cancer
Interventions
Erlotinib, gemcitabine
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
2
States / cities
Los Angeles, California • Sacramento, California
Source: ClinicalTrials.gov public record
Updated Jan 10, 2018 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional

A Phase I Study of the Safety and Immunogenicity of Rgp 120/HIV-1IIIB Vaccine in HIV-1 Seropositive Adult Volunteers

NCT00001992
View directory record Official record
Conditions
HIV Infections
Interventions
rgp120/HIV-1IIIB
Biological
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
U.S. locations
1
States / cities
Rockville, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 24, 2005 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional

A Study of DMOT4039A in Participants With Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

NCT01469793
View directory record Official record
Conditions
Ovarian Cancer
Interventions
DMOT4039A
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
71 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
4
States / cities
Phoenix, Arizona • Aurora, Colorado • Jacksonville, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2017 · Synced Oct 21, 2026, 5:52 PM EDT
Recruiting Phase 2 Interventional

A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics (PK) of RO7837195 in Participants With Moderately to Severely Active Ulcerative Colitis (UC)

NCT06979336
View directory record Official record
Conditions
Ulcerative Colitis
Interventions
RO7837195, RO7837195 Matched Placebo
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
224 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
8
States / cities
Lancaster, California • San Diego, California • Colorado Springs, Colorado + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 28, 2026 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Results available

Preoperative Bevacizumab and Trastuzumab With ABI-007 and Carboplatin in HER2+ Breast Cancer

NCT00392392
View directory record Official record
Conditions
Breast Cancer
Interventions
nab-paclitaxel, Bevacizumab, Trastuzumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older · Female only
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
6
States / cities
Fort Myers, Florida • Orlando, Florida • Gainesville, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 20, 2013 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of GDC-0623 in Patients With Locally Advanced or Metastatic Solid Tumors

NCT01106599
View directory record Official record
Conditions
Solid Cancers
Interventions
GDC-0623
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
4
States / cities
Los Angeles, California • Sacramento, California • Oklahoma City, Oklahoma + 1 more
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 21, 2026, 5:52 PM EDT
Terminated Not applicable Interventional Results available

Study of Adults With Low Growth Hormone Who Survived Childhood Cancer Where Treatment Caused Low Bone Density

NCT00145704
View directory record Official record
Conditions
Osteopenia
Interventions
bisphosphonate therapy (risedronate), Vitamin D supplement, Calcium
Drug · Dietary Supplement
Lead sponsor
State University of New York - Upstate Medical University
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2008
U.S. locations
1
States / cities
Syracuse, New York
Source: ClinicalTrials.gov public record
Updated Apr 8, 2013 · Synced Oct 21, 2026, 5:52 PM EDT
Withdrawn Phase 3 Interventional

Pulmozyme in Cystic Fibrosis With Sinusitis

NCT01155752
View directory record Official record
Conditions
Sinusitis, Cystic Fibrosis
Interventions
Pulmozyme single use ampule, placebo
Drug
Lead sponsor
Milton S. Hershey Medical Center
Other
Eligibility
12 Years to 65 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Hershey, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 21, 2017 · Synced Oct 21, 2026, 5:52 PM EDT
Completed No phase listed Observational

Understanding Value in Metastatic Breast Cancer

NCT03257917
View directory record Official record
Conditions
Metastatic Breast Cancer
Interventions
Understanding value in Metastatic Breast Cancer
Other
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
18 Years to 90 Years · Female only
Enrollment
100 participants
Timeline
2017 – 2019
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 21, 2026, 5:52 PM EDT
Recruiting Phase 1Phase 2 Interventional

Mosunetuzumab With Chemotherapy for the Treatment of Patients With Untreated C-Myc Rearrangement Positive High Grade B Cell Lymphoma or Diffuse Large B Cell Lymphoma

NCT06249191
View directory record Official record
Conditions
Diffuse Large B-Cell Lymphoma, High Grade B-Cell Lymphoma
Interventions
Biopsy, Biospecimen Collection, Bone Marrow Aspiration and Biopsy, Computed Tomography, Cyclophosphamide, Doxorubicin, Echocardiography, Etoposide, Magnetic Resonance Imaging, Mosunetuzumab, Multigated Acquisition Scan, Positron Emission Tomography, Prednisone, Vincristine
Procedure · Drug · Biological
Lead sponsor
OHSU Knight Cancer Institute
Other
Eligibility
18 Years to 75 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 1 Interventional

Safety/Biomarker Study of CNTO 95 and Avastin in Solid Tumors

NCT00888043
View directory record Official record
Conditions
Solid Tumors
Interventions
CNTO 95 and avastin
Drug
Lead sponsor
Herbert Hurwitz, MD
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 11, 2015 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Results available

Study of Bevacizumab + mFOLFOX6 Versus Bevacizumab + FOLFIRI With Biomarker Stratification in Participants With Previously Untreated Metastatic Colorectal Cancer (mCRC)

NCT01374425
View directory record Official record
Conditions
Colorectal Cancer
Interventions
5-Fluorouracil, Bevacizumab, Irinotecan, Leucovorin, Oxaliplatin, Capecitabine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
376 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
65
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Bellflower, California + 59 more
Source: ClinicalTrials.gov public record
Updated Aug 11, 2016 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Results available

A Pilot Study of Rituximab for the Anticoagulation Resistant Manifestations of Antiphospholipid Syndrome

NCT00537290
View directory record Official record
Conditions
Antiphospholipid Syndrome
Interventions
Rituximab
Drug
Lead sponsor
Hospital for Special Surgery, New York
Other
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 31, 2017 · Synced Oct 21, 2026, 5:52 PM EDT
Active, not recruiting Phase 2 Interventional Results available

T-DM1+Pertuzumab in Pre-OP Early-Stage HER2+ BRCA

NCT02326974
View directory record Official record
Conditions
HER-2 Positive Breast Cancer, Breast Cancer, Stage II Breast Cancer, Stage III Breast Cancer
Interventions
T-DM1, Pertuzumab, Excision of tumor/mastectomy
Drug · Procedure
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
164 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2028
U.S. locations
4
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 2, 2026 · Synced Oct 21, 2026, 5:52 PM EDT
Recruiting Phase 1Phase 2 Interventional

Atezolizumab Plus Tivozanib in Immunologically Cold Tumor Types

NCT05000294
View directory record Official record
Conditions
Bile Duct Cancer, Gall Bladder Cancer, Breast Cancer, Neuroendocrine Tumors, Ovarian Cancer, Pancreatic Adenocarcinoma, Soft Tissue Sarcoma, Vulvar Cancer, Prostate Cancer
Interventions
Atezolizumab, Tivozanib
Drug
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 99 Years
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Jul 13, 2026 · Synced Oct 21, 2026, 5:52 PM EDT
Terminated Phase 2 Interventional Results available

Trial of the Combination of Bevacizumab and Everolimus in Patients With Refractory, Progressive Intracranial Meningioma

NCT00972335
View directory record Official record
Conditions
Intracranial Meningioma
Interventions
Everolimus, Bevacizumab
Drug
Lead sponsor
SCRI Development Innovations, LLC
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
7
States / cities
Orlando, Florida • Louisville, Kentucky • Omaha, Nebraska + 4 more
Source: ClinicalTrials.gov public record
Updated Nov 10, 2021 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 2 Interventional

Phase 2 Study of ABT-869 in Advanced Hepatocellular Carcinoma (HCC)

NCT00517920
View directory record Official record
Conditions
Advanced Hepatocellular Carcinoma
Interventions
ABT-869
Drug
Lead sponsor
AbbVie (prior sponsor, Abbott)
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 4, 2013 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Results available

A Study to Evaluate the Long-Term Safety and Efficacy of GDC-0853 in Participants With Moderate to Severe Rheumatoid Arthritis Enrolled in Study GA29350

NCT02983227
View directory record Official record
Conditions
Rheumatoid Arthritis
Interventions
GDC-0853
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years to 76 Years
Enrollment
496 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2019
U.S. locations
11
States / cities
Glendale, Arizona • Covina, California • El Cajon, California + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 3, 2020 · Synced Oct 21, 2026, 5:52 PM EDT
Completed Phase 2 Interventional Results available

A Study of the Efficacy of ABT-199 in Subjects With Relapsed/Refractory or Previously Untreated Chronic Lymphocytic Leukemia With the 17p Deletion

NCT01889186
View directory record Official record
Conditions
Chronic Lymphocytic Leukemia, 17p Deletion, Cancer of the Blood and Bone Marrow
Interventions
ABT-199 (Main Cohort), ABT-199 (Safety Expansion Cohort)
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 99 Years
Enrollment
158 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2020
U.S. locations
16
States / cities
Tucson, Arizona • Duarte, California • La Jolla, California + 11 more
Source: ClinicalTrials.gov public record
Updated Dec 16, 2021 · Synced Oct 21, 2026, 5:52 PM EDT
Recruiting No phase listed Observational

Exploring the Physiologic, Pharmacodynamic, and Clinical Responses of Skeletal Muscle in Patients With Spinal Muscular Atrophy Treated With SMN-Directed Therapies

NCT06532474
View directory record Official record
Conditions
Spinal Muscular Atrophy
Interventions
Not listed
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
5 Years to 20 Years
Enrollment
24 participants
Timeline
2025 – 2028
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 9, 2026 · Synced Oct 21, 2026, 5:52 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of the BL-8040 and Atezolizumab for Maintenance Treatment in Subjects With Acute Myeloid Leukemia (AML)

NCT03154827
View directory record Official record
Conditions
Acute Myeloid Leukemia
Interventions
BL-8040, Atezolizumab
Drug
Lead sponsor
BioLineRx, Ltd.
Industry
Eligibility
60 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
2
States / cities
Houston, Texas • Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 21, 2026, 5:52 PM EDT